Lilly to acquire ICOS in $2.1 billion deal

Share this article:
Eli Lilly has agreed to purchase ICOS, co-marketer of erectile dysfunction drug Cialis (tadalfil), for approximately $2.1 billion. Lilly and ICOS have been partners in Cialis since 1998 and launched the drug together in 2003, capturing 25% of the ED market in the US. “This transaction provides financial and operation al benefits to Lilly,” said CEO Sidney Taurel in a statement. “We also look forward to further developing the commercial potential of tadalfil through the pursuit of new indications.” The deal is expected to close in late 2006 or early 2007, with positive earnings results by 2008. In July, Lilly reported Cialis sales jumped 22% in the second quarter to $233.2 million. Lilly is scheduled to report its third quarter results Thursday.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.